Malignant Eye Neoplasm — Trials

Malignant Eye Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

446 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 83
Recruiting: 44
Ph III recruiting: 10
Growth YoY: —
Industry share: 30%
Top sponsor: IDEAYA Biosciences
Termination share: 33.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (67)

clinicaltrialsPublishedShowing 51–56 of 56 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00933985	Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia	terminated	Phase 1	22	National Cancer Institute (NCI)NIH	2	May 1, 2014	clinicaltrials
NCT00101205	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	terminated	Phase 1	40	National Cancer Institute (NCI)NIH	1	Feb 24, 2014